BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	56.90M
Revenue (ttm)	42.01K
Net Income (ttm)	-6.48M
Shares Out	113.80M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	368,430
Average Volume	206,523
Open	0.530
Previous Close	0.540
Day's Range	0.490 - 0.530
52-Week Range	0.170 - 0.670
Beta	0.50
RSI	62.35
Earnings Date	Apr 22, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2023, BioNxt Solutions's revenue was 372,247, an increase of 25.15% compared to the previous year's 297,442. Losses were -7.72 million, -37.60% less than in 2022.